Menopause and menopausal status in a woman
The paper provides a systems analysis of the data available in modern literature on possible methods for correcting menopausal disorders in peri- and postmenopausal women.It sets forth in detail the following aspects: classification; characteristics of the stages of reproductive system aging; pathogenesis; clinical manifestations of menopausal conditions; laboratory and instrumental diagnosis; principles of hormonal and non-hormonal therapy for menopausal disorders; and prevention of long-term menopausal complications. Menopausal hormone therapy is shown to be an effective method to correct menopausal symptoms, but it has certain risks and side effects. In this connection, further investigations are required to search for new non-hormonal treatments for menopausal disorders.Yureneva S.V., Ermakova E.I.
Keywords
menopause
menopausal transition period
postmenopause
estrogen deficiency
menopausal disorders
hot flushes
menopausal hormone therapy
References
1. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4): 387-95.
2. Сухих Г.Т., Сметник В.П., Андреева Е.Н., Балан В.Е., Гависова А.А., Григорян О.Р., Ермакова Е.И., Зайдиева Я.З., Ильина Л.М., Касян В.Н., Марченко Л.А., Подзолкова Н.М., Роговская С.И., Сметник А.А., Чернуха Г.Е., Юренева С.В. Менопаузальная гормонотерапия и сохранение здоровья женщин в зрелом возрасте. Клинические рекомендации. М.; 2015. [Sukhikh G.T., Smetnik V.P., Andreeva E.N., Balan V.E., Gavisova A.A., Grigoryan O.R., Ermakova E.I., Zaidieva Ya.Z., Ilyina L.M., Kasyan V.N., Marchenko L.A., Podzolkova N.M., Rogovskaya S.I., Smetnik A.A., Chernukha G.E., Yureneva S.V. Menopausal hormone therapy and the preservation of women’s health in adulthood. Clinical recommendations. Moscow; 2015. (in Russian)]
3. Schoenaker D.A., Jackson C.A., Rowlands J.V., Mishra G.D. Socioeconomic position, lifestyle factors and age at natural menopause: a systematic review and meta-analyses of studies across six continents. Int. J. Epidemiol. 2014; 43(5): 1542-62.
4. Randolph J.F. Jr., Zheng H., Sowers M.R., Crandall C., Crawford S., Gold E.B., Vuga M. Change in follicle-stimulating hormone and estradiol across the menopausal transition: effect of age at the final menstrual period. J. Clin. Endocrinol. Metab. 2011; 96(3): 746-54.
5. Mishra G.D., Dobson A.J. Using longitudinal profiles to characterize women’s symptoms through midlife: results from a large prospective study. Menopause. 2012; 19(5): 549-55.
6. Freeman E.W., Sammel M.D., Sanders R.J. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014; 21(4): 339-46.
7. Юренева С.В., Ермакова Е.И., Павлович С.В., Корнеева И.Е., Смольникова В.Ю., Мишиева Н.Г. Ведение женщин с менопаузальными расстройствами. Учебное пособие. М.: ГЭОТАР-Медиа; 2016: 23-6. [Yureneva S.V., Ermakova E.I., Pavlovich S.V., Korneeva I.E., Smolnikova V.Yu., Mishieva N.G. Management of women with menopausal disorders. Tutorial. Moscow: GEOTAR-Media; 2016: 23-6. (in Russian)]
8. Lambrinoudaki I., Augoulea A., Armeni E., Rizos D., Alexandrou A., Creatsa M. et al. Menopausal symptoms are associated with subclinical atherosclerosis in healthy recently postmenopausal women. Climacteric. 2012; 15(4): 350-7.
9. Lee S.W., Jo H.H., Kim M.R., Kwon D.J., You Y.O., Kim J.H. Association between menopausal symptoms and metabolic syndrome in postmenopausal women. Arch. Gynecol. Obstet. 2012; 285(2): 541-8.
10. Franco O.H., Muka T., Colpani V., Kunutsor S., Chowdhury S., Chowdhury R., Kavousi M. Vasomotor symptoms in women and cardiovascular risk markers: systematic review and meta-analysis. Maturitas. 2015; 81(3): 353-61.
11. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause. 2013; 20(9): 888-902.
12. Portman D.J., Gass M.L. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women’s Sexual Health and The North American Menopause Society. Menopause. 2014; 21(10): 1063-8.
13. Sapir-Koren R., Livshits G. Is interaction between age-dependent decline in mechanical stimulation and osteocyte-estrogen receptor levels the culprit for postmenopausal-impaired bone formation? Osteoporos. Int. 2013; 24(6): 1771-89.
14. Gartoulla P., Islam M.R., Bell R.J., Davis S.R. Prevalence of menopausal symptoms in Australian women at midlife: a systematic review. Climacteric. 2014; 17(5): 529-39.
15. Avis N.E., Crawford S.L., Greendale G., Bromberger J.T., Everson-Rose S.A., Gold E.B. et al.; the Study of Women’s Health Across the Nation (SWAN). Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern. Med. 2015; 175(4): 531-9.
16. Baber R.J., Panay N., Fenton A.; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016; 19(2): 109-50.
17. The NAMS 2017 Hormone Therapy Position Statement Advisory Panel. The 2017 hormone therapy position statement of The North American Menopause Society NAMS. Menopause. 2017; 24(7): 728-53.
18. de Villiers T., Gass M.L., Haines C.J., Hall J.E., Lobo R.A., Pierroz D.D., Rees M. Global consensus statement on menopausal hormone therapy. Climacteric. 2013; 16(2): 203-4.
19. Corbelli J., Shaikh N., Wessel C., Hess R. Low-dose transdermal estradiol for vasomotor symptoms: a systematic review. Menopause. 2015; 22(1): 114-21.
20. Rees M., Pérez-López F.R., Ceasu I., Depypere H., Erel T., Lambrinoudaki I. et al. EMAS clinical guide: low-dose vaginal estrogens for postmenopausal vaginal atrophy. Maturitas. 2012; 73(2): 171-4.
21. Rahn D.D., Ward R.M., Sanses T.V., Carberry C., Mamik M.M., Meriwether K.V. et al.; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. Int. Urogynecol. J. 2015;26(1): 3-13.
22. Shane E., Burr D., Abrahamsen B., Adler R.A., Brown T.D., Cheung A.M. et al. Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J. Bone Miner. Res. 2014; 29(1): 1-23.
23. Renoux C., Dell’aniello S., Garbe E., Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ. 2010; 340: c2519.
24. De Villiers T.J., Stevenson J.C. The WHI: the effect of hormone replacement therapy on fracture prevention. Climacteric. 2012; 15(3): 263-6.
25. Pérez-López F.R., Ornat L., Ceausu I., Depypere H., Erel C.T., Lambrinoudaki I. et al. EMAS position statement: management of uterine fibroids. Maturitas. 2014; 79(1): 106-16.
26. Marret H., Fritel X., Ouldamer L., Bendifallah S., Brun J.L., De Jesus I. et al. Therapeutic management of uterine fibroid tumors: updated French guidelines. Eur. J. Obstet. Gynecol. Reprod. Biol. 2012; 165(2): 156-64.
27. Cobin R.H., Goodman N.F.; AACE Reproductive Endocrinology Scientific Committee. American Association of clinical endocrinologists and American college of endocrinology position statement on menopause. Endocr. Pract. 2017; 23(7): 869-80.
28. Moen M.H., Rees M., Brincat M., Erel T., Gambacciani M., Lambrinoudaki I. et al.; Menopause and Andropause Society. EMAS position statement: Managing the menopause in women with a past history of endometriosis. Maturitas. 2010; 67(1): 94-7.
29. Webber L., Davies M., Anderson R., Bartlett J., Braat D., Cartwright B.; The ESHRE Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum. Reprod. 2016; 31(5): 926-37.
30. Mintziori G., Lambrinoudaki I., Goulis D.G., Ceausu I., Depypere H., Erel C.T. et al. EMAS position statement: non-hormonal management of menopausal vasomotor symptom. Maturitas. 2015; 81(3): 410-3.
31. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015; 22(11): 1155-74.
32. Taylor-Swanson L., Thomas A., Ismail R., Schnall J.G., Cray L., Mitchell E.S., Woods N.F. Effects of traditional Chinese medicine on symptom clusters during the menopausal transition. Climacteric. 2015; 18(2): 142-56.
33. Shakeri F., Taavoni S., Goushegir A., Haghani H. Effectiveness of red clover in alleviating menopausal symptoms: a 12-week randomized, controlled trial. Climacteric. 2015; 18(4): 568-73.
34. Taku K., Melby M.K., Kronenberg F., Kurzer M.S., Messina M. Extracted or synthesized soybean isoflavones reduce menopausal hot flash frequency and severity: systematic review and meta-analysis of randomized controlled trials. Menopause. 2012; 19(7): 776-90.
35. Bordeleau L., Pritchard K.I., Loprinzi C.L., Ennis M., Jugovic O., Warr D. et al. Multicenter, randomized, cross-over clinical trial of venlafaxine versus gabapentin for the management of hot flashes in breast cancer survivors. J. Clin. Oncol. 2010; 28(35): 5147-52.
36. Eckel R.H., Jakicic J.M., Ard J.D., de Jesus J.M., Houston Miller N., Hubbard V.S. et al. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology American/Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(25, Suppl. 2): S76-99.
37. Gold E.B., Crawford S.L., Avis N.E., Crandall C.J., Matthews K.A., Waetjen L.E. et al. Factors related to age at natural menopause: longitudinal analyses from SWAN. Am. J. Epidemiol. 2013; 178(1): 70-83.
38. Samieri C., Sun Q., Townsend M.K., Chiuve S.E., Okereke O.I., Willett W.C. et al. The association between dietary patterns at midlife and health in aging: an observational study. Ann. Intern. Med. 2013; 159(9): 584-91.
39. Howe M., Leidal A., Montgomery D., Jackson E. Role of cigarette smoking and gender in acute coronary syndrome events. Am. J. Cardiol. 2011; 108(10): 1382-6.
40. Kline J., Tang A., Levin B. Smoking, alcohol and caffeine in relation to two hormonal indicators of ovarian age during the reproductive years. Maturitas. 2016; 92: 115-22.
41. Henderson V.W. Three midlife strategies to prevent cognitive impairment due to Alzheimer’s disease. Climacteric. 2014; 17(Suppl. 2):38-46.
42. Maki P.M. Critical window hypothesis of hormone therapy and cognition: a scientific update on clinical studies. Menopause. 2013; 20(6): 695-709.
Received 04.08.2017
Accepted 22.09.2017
About the Authors
S.V. Yureneva, Doctor of Medical Sciences, general research staff, Research Center of Obstetrics, Gynecology and Perinatology, Minostry of Health of Russia.117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +79161797400. E-mail syureneva@gmail.ru
E.I. Ermakova, Candidate of Medical Sciences, senior research staff, Research Center of Obstetrics, Gynecology and Perinatology, Minostry of Health of Russia.
117997, Russia, Moscow, Ac. Oparina str. 4. Tel.: +79168483746. E-mail ermakova.health@mail.ru
For citations: Yureneva S.V., Ermakova E.I. Menopause and menopausal status in a woman. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (7): 32-8. (in Russian)
https://dx.doi.org/10.18565/aig.2018.7.32-38
Similar Articles
